165 related articles for article (PubMed ID: 18804034)
1. Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.
Lai TS; Liu Y; Tucker T; Daniel KR; Sane DC; Toone E; Burke JR; Strittmatter WJ; Greenberg CS
Chem Biol; 2008 Sep; 15(9):969-78. PubMed ID: 18804034
[TBL] [Abstract][Full Text] [Related]
2. Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation.
Lai TS; Davies C; Greenberg CS
Protein Sci; 2010 Feb; 19(2):229-35. PubMed ID: 19998405
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Case A; Stein RL
Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.
Akbar A; McNeil NMR; Albert MR; Ta V; Adhikary G; Bourgeois K; Eckert RL; Keillor JW
J Med Chem; 2017 Sep; 60(18):7910-7927. PubMed ID: 28858494
[TBL] [Abstract][Full Text] [Related]
5. TGM2 and implications for human disease: role of alternative splicing.
Lai TS; Greenberg CS
Front Biosci (Landmark Ed); 2013 Jan; 18(2):504-19. PubMed ID: 23276939
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transglutaminase 2 reduces efferocytosis in human macrophages: Role of CD14 and SR-AI receptors.
Eligini S; Fiorelli S; Tremoli E; Colli S
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):922-30. PubMed ID: 27378395
[TBL] [Abstract][Full Text] [Related]
7. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
8. Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors.
Case A; Ni J; Yeh LA; Stein RL
Anal Biochem; 2005 Mar; 338(2):237-44. PubMed ID: 15745743
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease.
Chen NX; O'Neill K; Chen X; Kiattisunthorn K; Gattone VH; Moe SM
Am J Nephrol; 2013; 37(3):191-8. PubMed ID: 23466870
[TBL] [Abstract][Full Text] [Related]
10. Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.
Thangaraju K; Király R; Demény MA; András Mótyán J; Fuxreiter M; Fésüs L
PLoS One; 2017; 12(3):e0172189. PubMed ID: 28248968
[TBL] [Abstract][Full Text] [Related]
11. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
Pardin C; Roy I; Lubell WD; Keillor JW
Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
[TBL] [Abstract][Full Text] [Related]
12. Tyrphostins are inhibitors of guanylyl and adenylyl cyclases.
Jaleel M; Shenoy AR; Visweswariah SS
Biochemistry; 2004 Jun; 43(25):8247-55. PubMed ID: 15209521
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase activity arising from Factor XIIIA is required for stabilization and conversion of plasma fibronectin into matrix in osteoblast cultures.
Cui C; Wang S; Myneni VD; Hitomi K; Kaartinen MT
Bone; 2014 Feb; 59():127-38. PubMed ID: 24246248
[TBL] [Abstract][Full Text] [Related]
14. Organization and chromosomal mapping of mouse Gh/tissue transglutaminase gene (Tgm2).
Nanda N; Iismaa SE; Copeland NG; Gilbert DJ; Jenkins N; Graham RM; Sutrave P
Arch Biochem Biophys; 1999 Jun; 366(1):151-6. PubMed ID: 10334875
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase inhibitors: a patent review.
Keillor JW; Apperley KY
Expert Opin Ther Pat; 2016; 26(1):49-63. PubMed ID: 26560530
[TBL] [Abstract][Full Text] [Related]
16. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress.
Matlung HL; Neele AE; Groen HC; van Gaalen K; Tuna BG; van Weert A; de Vos J; Wentzel JJ; Hoogenboezem M; van Buul JD; VanBavel E; Bakker EN
Atherosclerosis; 2012 Oct; 224(2):355-62. PubMed ID: 22921425
[TBL] [Abstract][Full Text] [Related]
18. Potential of transglutaminase 2 as a therapeutic target.
Caccamo D; Currò M; Ientile R
Expert Opin Ther Targets; 2010 Sep; 14(9):989-1003. PubMed ID: 20670177
[TBL] [Abstract][Full Text] [Related]
19. Potent transglutaminase inhibitors, dithio β-aminoethyl ketones.
Ozaki S; Ebisui E; Hamada K; Suzuki AZ; Terauchi A; Mikoshiba K
Bioorg Med Chem Lett; 2011 Jan; 21(1):377-9. PubMed ID: 21134746
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]